Myelodysplastic syndromes are early cancers, study confirms

For many years there has been confusion about what exactly myelodysplastic syndromes (MDS) are: chronic blood disorders, pre-cancerous conditions, pre-leukemias, etc. Thanks to researchers from Washington University at the Siteman Cancer Center, it is clearer than ever that MDS are early forms of cancer.

Their work, published in the New England Journal of Medicine, used DNA sequencing technology to track the genetic evolution of MDS in seven patients whose disorders transformed into fatal acute myeloid leukemia.

They identified the so-called 'founding clone' in each patient's disease--the mutation that launched the disease in the first place--then tracked secondary clones as the disease progressed.

In doing so they determined that even in the very early stages of MDS in patients whose disease progresses into AML, as much as 85 percent of the patient's bone marrow cells were already malignant--a discovery that could aide doctors in prognosis.

Furthermore, they found that targeting mutations that occurred later with therapies was largely pointless because the founding clone remained unaffected; to that end, therapies should target the founding mutations in order to be effective.

Source: NEJM

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap